常山药业(300255) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 189,613,515.77, a decrease of 12.32% year-over-year[4] - Net profit attributable to shareholders was CNY -15,728,432.84, down 129.02% compared to the same period last year[4] - Basic and diluted earnings per share were both CNY -0.02, reflecting a decline of 133.33% year-over-year[4] - Total operating revenue decreased to ¥681,221,459.23 from ¥784,021,902.08, representing a decline of approximately 13.1% year-over-year[19] - Net profit for the period was -¥56,983,632.04, compared to -¥27,806,023.52 in the previous period, indicating a worsening of approximately 104.1%[20] - The total comprehensive income for the period was -¥57,237,822.00, compared to -¥27,804,018.75 in the previous period, indicating a decline of approximately 106.5%[20] - The company reported a basic earnings per share of -¥0.05, compared to ¥0.01 in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,657,584,588.98, an increase of 2.98% from the end of the previous year[4] - The total assets of Hebei Changshan Biochemical Pharmaceutical Co., Ltd. as of September 30, 2025, amounted to CNY 4,657,584,588.98, an increase from CNY 4,522,760,540.58 at the beginning of the period[16] - Current assets totaled CNY 2,077,304,073.35, up from CNY 2,002,412,631.48 at the beginning of the period, reflecting a growth of approximately 3.9%[16] - Total liabilities rose to CNY 3,179,083,140.13 from CNY 2,987,021,269.73, reflecting an increase of about 6.4%[17] - The company's equity remained stable with total equity at CNY 1,478,501,448.85, unchanged from the previous period[17] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 142,350,749.85, down 5.32%[4] - Cash flow from operating activities generated ¥142,350,749.85, down from ¥150,346,631.17, a decrease of about 5.3% year-over-year[21] - Cash flow from investing activities increased by 39.04% year-over-year, mainly due to reduced cash payments for fixed assets and other long-term assets[10] - Net cash flow from investing activities was -$72.1 million, an improvement from -$118.3 million year-over-year[22] - Cash inflow from financing activities totaled $2.07 billion, compared to $1.71 billion in the previous year[22] - Cash outflow from financing activities was $2.13 billion, up from $1.65 billion year-over-year[22] - Net cash flow from financing activities was -$61.9 million, a decline from a positive $51.0 million in the previous year[22] - The net increase in cash and cash equivalents was $11.2 million, down from $83.3 million year-over-year[22] - The ending balance of cash and cash equivalents was $247.0 million, compared to $314.2 million at the end of the previous year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 46,618[11] Strategic Focus - The company plans to continue focusing on R&D for new products and technologies to enhance market competitiveness[15] - Future guidance indicates a strategic emphasis on market expansion and potential mergers and acquisitions to drive growth[15] Operational Efficiency - Sales expenses decreased by 64.22% year-over-year, attributed to the inclusion of products in national procurement and adjustments in sales strategy[9] - Investment income increased by 100.00% year-over-year due to gains from the disposal of a subsidiary[9] - Research and development expenses increased slightly to ¥24,568,492.79 from ¥23,438,244.55, reflecting a growth of approximately 4.8%[19] - Other income decreased significantly to ¥5,567,369.76 from ¥30,589,042.11, a decline of about 81.8% year-over-year[19] - The company recorded credit impairment losses of ¥7,201,497.18, up from ¥531,492.70, marking an increase of approximately 1255.5% year-over-year[20] Inventory and Receivables - Accounts receivable rose to CNY 310,502,510.21 from CNY 253,625,332.05, indicating an increase of approximately 22.4%[16] - Inventory decreased to CNY 1,341,817,413.22 from CNY 1,385,747,770.05, showing a decline of about 3.2%[16] Borrowings - Short-term borrowings increased by 47.98% compared to the beginning of the period, indicating a rise in borrowing[7] - Short-term borrowings increased significantly to CNY 1,313,433,777.78 from CNY 887,546,719.51, marking an increase of approximately 48.0%[17] Audit Status - The third quarter financial report was not audited[23]